Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Arthurs, Benjamin, Wunderle, Kathy, Hsu, Maylee, Kim, Suil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369366/
https://www.ncbi.nlm.nih.gov/pubmed/28377877
http://dx.doi.org/10.1016/j.rmcr.2017.03.011
Descripción
Sumario:We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clinicians should be aware of potential Aspergillus infections in patients treated with this drug.

Ejemplares similares